Cagrilintide: A Long-Acting Amylin Analogue for Metabolic Research

Research summary. Cagrilintide (development code AM833) is a long-acting synthetic analogue of human amylin developed by Novo Nordisk. Amylin is a 37-amino-acid peptide co-secreted with insulin by pancreatic β-cells; it slows gastric emptying, suppresses post-prandial glucagon secretion, and promotes satiety through engagement of receptors in the area postrema. Cagrilintide was engineered to retain these activities while extending plasma half-life sufficiently for once-weekly administration in clinical investigation.

Molecular profile

• Class: Long-acting amylin / calcitonin-receptor co-agonist (selective at AMY1R, AMY2R, AMY3R)
• Origin: Engineered analogue based on human amylin and salmon calcitonin templates
• Half-life: Approximately 7 days in human pharmacokinetic studies, supporting once-weekly dosing
• Modification strategy: Amino-acid substitutions to prevent amyloid fibril formation, plus a fatty-acid acylation to enable albumin binding and extend half-life

Native human amylin is notoriously prone to forming amyloid fibrils — a property linked to β-cell dysfunction in type 2 diabetes and to the limited drug-development utility of human amylin itself. Earlier amylin-derived therapeutics, such as pramlintide, drew on the more soluble salmon calcitonin sequence as a template. Cagrilintide builds on this strategy with additional substitutions and a C18 fatty-acid linker analogous to those used in semaglutide and tirzepatide.

Mechanism of action

Cagrilintide engages the heterodimeric amylin receptor family, which is formed by association of the calcitonin receptor (CTR) with one of three receptor activity-modifying proteins (RAMP1, RAMP2, RAMP3) to produce AMY1R, AMY2R, and AMY3R subtypes. Activation of these receptors in the area postrema and other circumventricular regions of the brain produces:

• Suppression of food intake through enhanced meal-related satiety signalling
• Slowing of gastric emptying
• Suppression of post-prandial glucagon secretion
• Modulation of hypothalamic energy-balance circuits

These mechanisms are complementary to, but distinct from, those of GLP-1 receptor agonists — which is the basis for combination strategies discussed below.

Preclinical and clinical research highlights

Preclinical models. Rodent studies of cagrilintide and related long-acting amylin analogues reported dose-dependent reductions in food intake and body weight, with effects sustained over chronic dosing. Combination studies with semaglutide showed greater-than-additive weight reduction.

Phase 1 human study. A randomised, placebo-controlled Phase 1 trial in adults with overweight or obesity, reported by Enebo and colleagues in 2021, evaluated escalating doses of cagrilintide alone and in combination with semaglutide 2.4 mg. Cagrilintide monotherapy produced dose-dependent reductions in body weight, and the combination of cagrilintide 4.5 mg with semaglutide 2.4 mg achieved greater weight reduction than either component alone over the 20-week study [1].

Phase 2 monotherapy. Subsequent Phase 2 work investigated cagrilintide as a monotherapy across a dose range of 0.3 mg to 4.5 mg weekly. The 4.5 mg dose produced a placebo-adjusted body-weight reduction in the range of 6–8% in adults with obesity over the trial duration.

Combination programmes. The combination of cagrilintide with semaglutide is being developed as the fixed-dose combination CagriSema (covered separately), which has progressed into Phase 3 trials for weight management and type 2 diabetes.

Why amylin biology matters here

The therapeutic logic for layering amylin and GLP-1 pharmacology is mechanistic rather than purely additive. GLP-1 receptor agonists primarily engage incretin and satiety circuits via the vagal–brainstem axis and hypothalamus, while amylin agonists engage the area postrema and modulate gastric emptying and glucagon. The two sets of receptors are anatomically and pharmacologically distinct, which has supported the hypothesis that combining the two can produce weight-loss effects exceeding those achievable with either pathway alone.

Current research status

Cagrilintide remains an investigational research peptide. It has not received marketing authorisation as a standalone therapeutic. Its principal development pathway is as a component of the CagriSema combination. Independent Phase 2 data on cagrilintide monotherapy are available in the published literature and clinical-trial registries.

For the research community, the molecule is a useful pharmacological probe for:

• Studying long-acting amylin pharmacology in metabolic models
• Investigating amylin/GLP-1 combination biology
• Examining tachyphylaxis and receptor desensitisation in chronic amylin signalling

Key takeaways for researchers

• Cagrilintide is a long-acting synthetic amylin analogue (development code AM833) engineered for once-weekly dosing.
• It engages the amylin receptor family (CTR + RAMP heterodimers) and modulates satiety, gastric emptying, and glucagon secretion.
• Phase 1 and Phase 2 human data support meaningful weight-loss activity, with greater effects observed in combination with semaglutide.
• It is the amylin component of the CagriSema fixed-dose combination programme.
• Cagrilintide is not approved as a standalone therapeutic.

References

1. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. The Lancet. 2021;397(10286):1736–1748.

---

This article is provided for educational and research purposes only. Cagrilintide is an investigational research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.